Skip Navigation

European Heart Journal 1990 11(Supplement F):29-35; doi:10.1093/eurheartj/11.suppl_F.29
Copyright © 1990 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hoffmann, J. J. M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoffmann, J. J. M. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1990 The European Society of Cardiology

Blood viscosity and platelet function in thrombolytic therapy of acute myocardial infarction

J. J. M. L. Hoffmann

Hemostasis Division, Department of Clinical Laboratories, Catharina Hospital Eindhoven, the Netherlands

Correspondence to: Dr J. Hoffmann, Dept. of Clinical Laboratories, Catharina Hospital, P.O. Box 1350, NL-5602 ZA Eindhoven, The Netherlands

The mechanisms by which thrombolytic drugs accomplish their impressive clinical effects in the treatment of acute myocardial infarction are as yet incompletely appreciated. Factors other than lysis of thrombi and restoration of blood flow most likely play a role, and blood viscosity and platelet function probably are important factors.

Blood viscosity is inversely related to oxygen supply to myocardial tissue and therefore a decrease in viscosity might contribute to presentation of myocardial function. Since fibrinogen is a major determinant of blood viscosity and this protein is largely degraded by some thrombolytic drugs, it is conceivable that a systemic fibrinogenolytic state is of additional benefit for the patient.

Fibrinogen and other plasma proteins which change during thrombolytic therapy are also essential for adequate platelet function. Besides, thrombolytic drugs can directly affect platelet activity. Although the exact effects are still unknown, it is certain that changes in platelet function induced by thrombolytic drugs are important for the clinical efficacy and probably for the side-effects of thrombolytic therapy.

Key Words: Acute myocardial infarction • blood viscosity • fibrinogen • fibrinolytic agents • plasminogen activators • platelet aggregation • platelet function • thrombolytic therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.